A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial
JMIR Research Protocols · 2026
DOI: 10.2196/89584 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, 2026. Verfasst von Yixuan Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infec…. Hauptthemen laut MEDLINE: Isoniazid, Latent Tuberculosis, Rifampin, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Close contacts of individuals with active pulmonary tuberculosis (TB) face an elevated risk of TB acquisition, necessitating systematic screening for latent TB infection and subsequent TB preventive treatment (TPT). Major TPT regimens require ≥3 months of drug exposure and demonstrate suboptimal safety profiles, significantly compromising treatment completion rates. Therefore, the development of shorter, safer chemoprophylaxis strategies represents a critical need in global TB control. Among close contacts, school-aged children and adolescents constitute the most vulnerable demographic subgroup, warranting prioritized intervention efforts.
Objective
The primary objective of this study is to demonstrate noninferiority of an ultrashort, 1-month TPT regimen of isoniazid plus rifapentine, administered 3 times a week (1H 3 P 3 ) compared with the standard 3-month daily isoniazid plus rifampicin (3HR) regimen in preventing active TB, as measured by the 24-month cumulative incidence of active TB following randomization.
Methods
An investigator-initiated, prospective, multicenter, open-label, noninferiority, cluster-randomized controlled clinical trial is being implemented under the auspices of the national TB control program in China. Close contacts of school pulmonary TB index cases, regardless of diagnostic type, are actively screened for symptoms using interferon-gamma release assays, chest imaging, and sputum molecular diagnostic testing to detect TB infection and exclude active TB. Eligible latent TB infection cases will be randomized in a 1:1 cluster ratio to receive either the standard 3HR regimen or the novel ultrashort 1H 3 P 3 regimen for TPT, with subsequent follow-up for up to 2 years to assess disease progression. The primary composite end point includes microbiologically confirmed TB (sputum culture or molecular diagnostic testing) or clinically diagnosed TB. With 80% power to detect noninferiority (20% margin), the study requires 1760 participants per arm, accounting for cluster design effects.
Results
Recruitment started in September 2023. By the end of December 2025, a total of 2478 participants, comprising 627 index cases, had been enrolled, and recruitment is estimated to continue until September 2026. Data analysis will commence after the 2-year follow-up period, and the results are expected to be published by March 2029.
Conclusions
This cluster randomized controlled trial aims to establish the noninferiority of a novel, ultrashort 1H 3 P 3 regimen compared to the standard 3-month 3HR regimen for preventing active TB in infected school contacts. If successful, this well-tolerated 1-month regimen could significantly improve treatment completion and optimize preventive therapy delivery in high-transmission congregate settings, thereby contributing substantively to global TB control efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, No.12 Middle Wulum…
- Clinical Research Department, Shanghai Sci-Tech Inno Center for Infectious & Immunity, Shanghai, Shanghai, China.
- Institute for Tuberculosis Control, Guizhou Center for Disease Control and Prevention, Guiyang, Guizhou, China.
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
- Department of Biostatistics, School of Public Health, Fudan University, Shanghai, Shanghai, China.
- See Acknowledgments.
ORCID-Profile: Yixuan Yang, Feiran Zhou, Yanfei Ren, Fudong Li, Qingluan Yang, Yuying He, Xiaoling Wei, Xing Wang, Jianfeng Luo, Feng Sun, Lingyun Shao, Jinlan Li, Qiaoling Ruan, Wenhong Zhang
Zitieren
APA
Yang, Y., Zhou, F., Ren, Y., Li, F., Yang, Q., He, Y., Wei, X., Wang, X., Luo, J., Sun, F., Shao, L., Li, J., Ruan, Q., & Zhang, W. (2026). A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/89584
Vancouver
Yang Y, Zhou F, Ren Y, Li F, Yang Q, He Y, et al. A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols. 2026. doi:10.2196/89584
BibTeX
@article{Yang2026,
author = {Yang, Yixuan and Zhou, Feiran and Ren, Yanfei and Li, Fudong and Yang, Qingluan and He, Yuying and Wei, Xiaoling and Wang, Xing and Luo, Jianfeng and Sun, Feng and Shao, Lingyun and Li, Jinlan and Ruan, Qiaoling and Zhang, Wenhong},
title = {A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2026},
doi = {10.2196/89584}
}
EUVIMED